May 7th 2024- Prof. Ibrahim Yakoub-Agha- Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
April 30th 2024- Dr. Fadi Haddad & Prof. Elias Jabbour- Phase 2 Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission
April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
March 25th 2024- Prof. Olaf Penack- Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation
March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
March 11th 2024- Dr. Adi Zoref Lorenz – Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Sweden: Incidence, Clinical Characteristics, and Survival
April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy
